NASDAQ:QTRX

Quanterix Stock Forecast, Price & News

$66.18

+5.37 (+8.83 %)

(As of 01/28/2021 10:56 AM ET)

Add

Compare

Today's Range

$62.14

Now: $66.18▼

$67.80

50-Day Range

$43.76

MA: $54.75▼

$80.28

52-Week Range

$10.90

Now: $66.18▼

$84.83

Volume4,351 shs

Average Volume475,252 shs

Market Capitalization$2.10 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.71

Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.22 out of 5 stars

Medical Sector

805th out of 1,926 stocks

Analytical Instruments Industry

16th out of 29 stocks

1.5 Analyst's Opinion

Consensus Rating
Quanterix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $58.33, Quanterix has a forecasted downside of 13.5% from its current price of $67.40.
Amount of Analyst Coverage
Quanterix has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Quanterix has received 246 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Quanterix has received 297 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Quanterix has received 54.70% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote “Outperform” if you believe QTRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Quanterix does not currently pay a dividend.
Dividend Growth
Quanterix does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quanterix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,109,353.00 in company stock.
Percentage Held by Insiders
Only 25.40% of the stock of Quanterix is held by insiders.
Percentage Held by Institutions
71.60% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Quanterix are expected to grow in the coming year, from ($0.91) to ($0.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quanterix is -59.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quanterix is -59.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Quanterix has a P/B Ratio of 14.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:QTRX

Previous Symbol

CUSIPN/A

CIK1503274

Webwww.quanterix.com

Phone617-301-9400

Employees248

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.01

Current Ratio7.65

Quick Ratio7.18

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$56.73 million

Price / Sales36.94

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.59 per share

Price / Book14.42

Profitability

EPS (Most Recent Fiscal Year)($1.63)

Net Income$-40,800,000.00

Net Margins-41.69%

Return on Equity-22.37%

Return on Assets-16.55%

Miscellaneous

Outstanding Shares31,668,000

Market Cap$2.10 billion

Next Earnings Date3/12/2021 (Estimated)

OptionableNot Optionable

$66.18

+5.37 (+8.83 %)

(As of 01/28/2021 10:56 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

Quanterix (NASDAQ:QTRX) Frequently Asked Questions

How has Quanterix's stock price been impacted by COVID-19?

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QTRX stock has increased by 243.2% and is now trading at $63.52.
View which stocks have been most impacted by COVID-19.

Is Quanterix a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Quanterix stock.
View analyst ratings for Quanterix or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Quanterix?

Wall Street analysts have given Quanterix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quanterix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Kevin Hrusovsky's approval rating as Quanterix's CEO?

15 employees have rated Quanterix CEO Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among Quanterix's employees.

When is Quanterix's next earnings date?

Quanterix is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Quanterix.

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) announced its earnings results on Thursday, November, 5th. The company reported $0.07 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.50. The firm earned $31.39 million during the quarter, compared to analysts' expectations of $15 million. Quanterix had a negative net margin of 41.69% and a negative trailing twelve-month return on equity of 22.37%.
View Quanterix's earnings history.

What guidance has Quanterix issued on next quarter's earnings?

Quanterix updated its fourth quarter 2020 IntraDay earnings guidance on Wednesday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20-22 million, compared to the consensus revenue estimate of $21.7 million.

What price target have analysts set for QTRX?

3 brokerages have issued 1-year price targets for Quanterix's stock. Their forecasts range from $40.00 to $75.00. On average, they expect Quanterix's share price to reach $58.33 in the next year. This suggests that the stock has a possible downside of 8.2%.
View analysts' price targets for Quanterix or view Wall Street analyst' top-rated stocks.

Are investors shorting Quanterix?

Quanterix saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 456,500 shares, a decrease of 17.9% from the December 15th total of 556,000 shares. Based on an average trading volume of 227,800 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.9% of the company's shares are sold short.
View Quanterix's Short Interest.

Who are some of Quanterix's key competitors?

Some companies that are related to Quanterix include Pacific Biosciences of California (PACB), Coherent (COHR), Berkeley Lights (BLI), Bionano Genomics (BNGO), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), EyePoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Precipio (PRPO), Astrotech (ASTC), HTG Molecular Diagnostics (HTGM), Scientific Industries (SCND), Pressure BioSciences (PBIO), BioForce Nanosciences (BFNH) and Arrayit (ARYC).
View all of QTRX's competitors.

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), The Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).

Who are Quanterix's key executives?

Quanterix's management team includes the following people:

Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 59, Pay $1.31M)
Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 68, Pay $41k)
Mr. Amol Chaubal, Chief Financial Officer (Age 45, Pay $501.87k)
Mr. John J. Fry, Gen. Counsel & Corp. Sec. (Age 60, Pay $465k)
Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 62)
Mr. William Geist, Chief Operating Officer
Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 50)
David Panzerella, VP of Sales
Dr. Mark T. Roskey, Sr. VP of Commercial & Accelerator (Age 61)
Dr. Dawn R. Mattoon Ph.D., Sr. VP of Research Products (Age 48)

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Who are Quanterix's major shareholders?

Quanterix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (4.74%), Strs Ohio (0.05%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix.

Which institutional investors are buying Quanterix stock?

QTRX stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Strs Ohio, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Quanterix or or view top insider-buying stocks.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $63.52.

How big of a company is Quanterix?

Quanterix has a market capitalization of $2.01 billion and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Quanterix employs 248 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is www.quanterix.com.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here